A novel approach to removing excess fluid through the skin and a new strategy to prevent right ventricular failure after LVAD ...

The clinical-stage genetic medicine company reported that LX2020 was generally well tolerated across ten participants, with ...

A new meta-analysis finds no clear long-term cardiovascular benefit from beta-blockers after myocardial infarction in ...

Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to ...

Patients with pre-existing high blood pressure are more likely to be susceptible to heart damage caused by anthracyclines, the most widely used chemotherapy drugs for cancer treatment for more than 30 ...

Morgans Scott Power positive of renewed momentum in the healthcare sector, which has risen 0.7% in the week ending January 16 ...

Shares of Lexeo Therapeutics (NASDAQ:LXEO) dropped about 17% on Monday after the company published interim Phase I/II results ...

“Rick is an accomplished executive with a proven track record in the medical device industry,” said Jason Spees, Chief Executive Officer at Impulse Dynamics®. “I am thrilled to welcome Rick to the ...

Solid Biosciences Inc. (Nasdaq: SLDB) (the "Company” or "Solid”), a life sciences company developing precision genetic ...

BMY reports positive late-stage data for Camzyos in adolescents with oHCM, expanding its cardiovascular outlook amid pipeline ...

Longer times from symptom onset to randomization equaled a smaller—or perhaps no—advantage for Impella vs standard care.

“This represents an important milestone in ensuring that Rapiblyk™ availability is secured nationwide, supporting clinicians and healthcare providers in critical care environments,” said John Kimmet, ...